Earnings Releases·Nov 2, 2026, 4:11 PM ET

Neurocrine Biosciences — Third Quarter 2026 Earnings Summary

Total revenues reached $1.123 billion, up 41% year-over-year, driven by INGREZZA ($801M, +17%), CRENESSITY ($211M, +115%), and new VYKAT XR sales ($107M); GAAP net income declined to $207 million ($1.96/share) from $210 million ($2.04/share) in the prior year, while Non-GAAP net income rose to $347 million ($3.29/share).
Full-year 2026 INGREZZA guidance was raised to $2.9–$2.925 billion, while GAAP and Non-GAAP SG&A guidance was lowered; IPR&D guidance increased to $34 million, with R&D and amortization guidance remaining unchanged.
The company announced the initiation of three new clinical studies: Phase 1 trials for obesity candidates NBIP-1968 and NBIP-2118, and a Phase 2 study for Alzheimer's candidate NBI-567, following the May 2026 acquisition of Soleno Therapeutics which added VYKAT XR and $2.2 billion in intellectual property.
Management anticipates meaningful growth opportunities in 2027 across the portfolio, with key clinical milestones expected including Phase 3 readouts for osavampator and direclidine, though total cash and marketable securities decreased to $790 million from $2.543 billion at year-end 2025.